Natalizumab Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 300mg
Reference Brands:
Category:
Multiple sclerosis
This injection is used in Multiple sclerosis. Multiple sclerosis is a condition which causes inflammation of the brain leading to nerve cell damages. This inflammation happens when white blood cells enters into the brain and spinal cord.
NATALIZUMAB INJECTION is available in Injection
and strengths such as 300mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, NATALIZUMAB INJECTION is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
NATALIZUMAB INJECTION can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
This injection stops the white blood cells getting through to the brain and thus reduces nerve damage caused by multiple sclerosis. It is used in reducing the signs and symptoms of Crohn’s disease. Inform your doctor if you have a medical condition such as HIV infection, leukemia or lymphoma, or an organ transplant, and others. The common side effects of this injection include fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea, rash, headache, upper respiratory tract infections, and nausea.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing